The Potential Impact of Tobacco Biopharming: The Case of Human Serum Albumin

Genti Kostandini, Bradford Mills and George Norton

American Journal of Agricultural Economics, 2006, vol. 88, issue 3, 671-679

Abstract: Biopharming stands to significantly expand the uses of many agricultural crops. This article examines the potential size and distribution of welfare gains from biopharming transgenic tobacco as a source of human serum albumin (HSA) using an economic surplus model under imperfect competition. The results suggest that HSA from transgenic tobacco will generate annual profits for the innovating firm of between $25 million and $49 million. On the other hand, consumers are unlikely to benefit during the patent life of the product given the innovator's market power. Copyright 2006, Oxford University Press.

Date: 2006
References: Add references at CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1111/j.1467-8276.2006.00887.x (application/pdf)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oup:ajagec:v:88:y:2006:i:3:p:671-679

Access Statistics for this article

American Journal of Agricultural Economics is currently edited by Madhu Khanna, Brian E. Roe, James Vercammen and JunJie Wu

More articles in American Journal of Agricultural Economics from Agricultural and Applied Economics Association Contact information at EDIRC.
Bibliographic data for series maintained by Oxford University Press ().